Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
amlodipine (amlodipine besilate), valsartan, hydrochlorothiazide
Novartis Pharma Stein AG
C09DX01
amlodipine (amlodipine besilate), valsartan, hydrochlorothiazide
10mg+ 160mg+ 25mg
tablets film-coated
(14/1x14), in blister, (28/2x14/), in blister
Prescription
Registered
2016-06-06
1 PACKAGE LEAFLET: INFORMATION FOR THE USER EXFORGE HCT 5 MG/160 MG/12.5 MG FILM-COATED TABLETS EXFORGE HCT 5 MG/160 MG/25 MG FILM-COATED TABLETS EXFORGE HCT 10 MG/160 MG/12.5 MG FILM-COATED TABLETS EXFORGE HCT 10 MG/160 MG/25 MG FILM-COATED TABLETS amlodipine/valsartan/hydrochlorothiazide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Exforge HCT is and what it is used for 2. What you need to know before you take Exforge HCT 3. How to take Exforge HCT 4. Possible side effects 5. How to store Exforge HCT 6. Contents of the pack and other information 1. WHAT EXFORGE HCT IS AND WHAT IT IS USED FOR Exforge HCT tablets contain three substances called amlodipine, valsartan and hydrochlorothiazide. All of these substances help to control high blood pressure. Amlodipine belongs to a group of substances called “calcium channel blockers”. Amlodipine stops calcium from moving into the blood vessel wall, which stops the blood vessels from tightening. Valsartan belongs to a group of substances called “angiotensin-II receptor antagonists”. Angiotensin II is produced by the body and makes the blood vessels tighten, thus increasing the blood pressure. Valsartan works by blocking the effect of angiotensin II. Hydrochlorothiazide belongs to a group of substances called “thiazide diuretics”. Hydrochlorothiazide increases urine output, which also lowers blood pressure. As a result of all three mechanisms, the blood vessels relax and blood pressure is lowered. Exforge HCT is used to treat h Read the complete document
68 1. NAME OF THE MEDICINAL PRODUCT Exforge HCT 10 mg/160 mg/25 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 25 mg of hydrochlorothiazide. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet) Brown-yellow, ovaloid, biconvex tablets with bevelled edge, debossed “NVR” on one side and “VHL” on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose of Exforge HCT is one tablet per day, to be taken preferably in the morning. Before switching to Exforge HCT patients should be controlled on stable doses of the monocomponents taken at the same time. The dose of Exforge HCT should be based on the doses of the individual components of the combination at the time of switching. The maximum recommended dose of Exforge HCT is 10 mg/320 mg/25 mg. _Special populations _ _Renal impairment _ Due to the hydrochlorothiazide component, Exforge HCT is contraindicated for use in patients with anuria (see section 4.3) and in patients with severe renal impairment (glomerular filtration rate (GFR) <30 ml/min/1.73 m 2 ) (see sections 4.3, 4.4 and 5.2). No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see sections 4.4 and 5.2). _Hepatic impairment _ Due to the valsartan component, Exforge HCT is contraindicated in patients with severe hepatic impairment (see section 4.3). In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Exforge HCT is not s Read the complete document